微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Patent ductus arteriosus
Patent ductus arteriosus

儿科

关键词儿科 疾病 先天性心脏病

词汇介绍

拓展阅读

解析

patent 英 /'pæt(ə)nt; 'peɪt(ə)nt/ 美 /'pætnt/

释    义   v. 取得……的专利权;授予专利     

adj. 专利的;特许生产或销售的;显著的;公开的;(脉管等)开放的     

n. 专利权;专利证;专利品

例    句   To introduce modified operation of patent arterial duct complicated with severe pulmonary hypertension and to study its feasibility, safety and indications. 介绍巨大动脉导管未闭合并重度肺动脉高压的一种改良术式及其可行性、安全性和适应症。

 

ductus 英 /'dʌktəs/  美 /'dʌktəs/

释    义   n. 导管

例    句   To explore the suitable depth of ductus insertion during nasal oxygen breath. 目的为探讨适宜的鼻导管吸氧时导管适宜的插入深度。


arteriosus

释    义   adj. 动脉的

例    句   Most babies have a closed ductus arteriosus by 72 hours after birth. 大多数婴儿在出生后72小时内动脉导管闭合。

概述

动脉导管未闭为小儿先天性心脏病常见类型之一。占先天性心脏病发病总数的10%,胎儿期动脉导管被动开放是血液循环的重要通道,出生后大约15小时即发生功能性关闭,80%在生后3个月解剖性关闭。到出生后1年,在解剖学上应完全关闭:若持续开放,并产生病理、生理改变,即称动脉导管未闭。但在某些先天性心脏病中,未闭的动脉导管可作为患儿生存的必须血流通道,自然关闭和手术堵闭可致死亡。充血性心力衰竭、心内膜炎等是常见的并发症。病理分型① 病理分型:管型:导管连接主动脉和肺动脉两端,粗细一致。②&n

Efficacy and safety of pharmacological treatments for Patent Ductus Arteriosus closure: a systematic review and network meta-analysis of clinical trials and observational studies复制标题

药物治疗动脉导管未闭的有效性和安全性: 临床试验和观察性研究的系统评价和网络荟萃分析

发表时间:2019-08-31

影响因子:5.6

作者: Marconi Ettore

期刊:Pharmacol Res

Efficacy and safety profiles of different pharmacological interventions used to treat patent ductus arteriosus(PDA) are relatively unexplored. Integrating the findings of randomized clinical trials (RCTs) with those from observational studies may provide key evidence on this important issue. We aimed at estimating the relative likelihood of failure to close the PDA, need for surgical closure, and occurrence of adverse events among preterm and full-term infants treated with indomethacin, ibuprofen, or acetaminophen, placebo, or no treatment including both RCTs and observational studies. We searched PubMed, Embase, and the Register of Controlled Trials from inception to October 30, 2018. We first estimated proportions of subjects with failure to close the PDA, subjects in whom surgical closure was performed after pharmacological treatment, death, and subjects with selected adverse events (AEs). These estimates were obtained using frequentist random-effect meta-analysis of arm-specific proportions. We then compared active drugs with each other and with control (either placebo or no treatment) by summarizing results at the end of treatment reported in the papers, regardless of number of administration(s), dose, route and type of administration, and study design and quality.

译文

不同药物干预治疗动脉导管未闭(pda)的疗效和安全性尚不清楚。将随机临床试验(rct)的结果与观察研究的结果结合起来,可以为这一重要问题提供关键证据。我们的目的是评估接受消炎痛、布洛芬或对乙酰氨基酚、安慰剂或不接受治疗(包括随机对照试验和观察研究)的早产儿和足月婴儿关闭PDA失败的相对可能性、手术关闭的必要性和不良事件的发生率。我们从一开始到2018年10月30日搜索了PubMed、EMBASE和对照试验注册。我们首先估计了未能关闭pda的受试者、在药物治疗后进行手术关闭的受试者、死亡的受试者和有选定不良事件(aes)的受试者的比例。这些估计值是通过对特定手臂比例的频率随机效应荟萃分析得出的。然后,我们通过总结论文中报告的治疗结束时的结果,将活性药物相互之间以及与对照药物(安慰剂或不治疗)进行比较,而不考虑给药次数、剂量、给药途径和类型,以及研究设计和质量。